News
SGMT
6.19
+1.98%
0.12
Weekly Report: what happened at SGMT last week (0406-0410)?
Weekly Report · 3d ago
Sagimet to Share Mid-Stage Liver Disease Drug Data at Medical Conference
Benzinga · 04/06 11:09
Sagimet grants 9,600 inducement stock options to new hire under Nasdaq rule exception
Reuters · 04/06 11:00
SAGIMET BIOSCIENCES ANNOUNCES POSTER AND ORAL PRESENTATIONS AT THE FUELING MASH: METABOLIC DRIVERS AND INFLAMMATORY CROSSTALK KEYSTONE SYMPOSIUM AND INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/06 11:00
Weekly Report: what happened at SGMT last week (0330-0403)?
Weekly Report · 04/06 10:34
Barclays Sticks to Their Hold Rating for Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 04/02 08:48
Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 03/31 20:00
Weekly Report: what happened at SGMT last week (0323-0327)?
Weekly Report · 03/30 10:34
Sagimet Biosciences initiated with a Buy at Rodman & Renshaw
TipRanks · 03/26 11:46
Weekly Report: what happened at SGMT last week (0316-0320)?
Weekly Report · 03/23 10:30
Guggenheim Keeps Their Buy Rating on Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 03/20 11:36
Weekly Report: what happened at SGMT last week (0309-0313)?
Weekly Report · 03/16 10:29
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)
TipRanks · 03/13 09:50
Sagimet: Advancing FASN Inhibitor Pipeline and Solid Cash Position Support Buy Rating and $26 Target
TipRanks · 03/12 18:05
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 03/12 17:10
Sagimet: Underappreciated, De-Risked Pipeline with Near-Term Milestones Supports Buy Rating
TipRanks · 03/12 15:25
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Tenet Healthcare (THC)
TipRanks · 03/12 12:20
Sagimet Biosciences GAAP EPS of -$0.29
Seeking Alpha · 03/11 19:35
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/11 18:30
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Dow Jones · 03/11 17:38
More
Webull provides a variety of real-time SGMT stock news. You can receive the latest news about Sagimet Biosciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.